Dante Labs, Cambridge Cancer Genomics, and Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, have signed a collaboration agreement.
The partnership aims to build the most comprehensive and patient-centric tumor profiling service enabling improved cancer patient management, treatment and monitoring. By combining Dante Labs’ experience and capacity in delivering a sequencing service for both solid tumor and cell free circulating tumor DNA from liquid biopsies, Nonacus’ sensitive targeted pan-cancer NGS libraries, and CCG.ai’s AI-powered software platform, OncOS, the companies will enable precision oncology at scale.
Oncologists and clinical researchers will be able to send samples for processing to Dante Labs, who will use library preparation kits from Nonacus and software from CCG.ai to create a sample to report solution. If there are actionable mutations, the report will recommend the right treatments for those mutations, if there are novel or unactionable mutations, the software will also be able to match possible clinical trials.
“Long turn-around time and lack of clinically oriented analysis are the main obstacles to fully deliver the potential of cancer genomics to patients. This partnership will provide the flexibility and accuracy that oncology professionals need to integrate cancer genomics into the care of their patients. The COVID pandemic has increased the backlog of genetic testing for cancer, potentially leaving many suspected cancers unconfirmed and treatments delayed. Dante Labs are one of the biggest clinical sequencing hub in Europe able to process large numbers of samples in high throughput. It is our hope that by combining AI software from CCG.ai and our library preparation kits, together we will be able to process samples and provide bioinformatic analysis critical to determining the best treatment path for patients. Only with this comprehensive content at scale will it be possible to address the COVID backlog,” Chris Sale, CEO of Nonacus, said.
“With cancer being one of the greatest healthcare challenges we are facing, this partnership opens the door to democratizing access to data-driven cancer treatment. Combining our industry leading precision oncology platform with Nonacus’ precise NGS solutions and Dante Labs’ fast and efficient NGS services provides customers with the ability to perform precision oncology at scale. The combined solution will enable oncologists to precisely and comprehensively profile a patient’s tumor and ultimately improve outcomes,” Nirmesh Patel, CSO at Cambridge Cancer Genomics, said.